HighTower Advisors’s Capricor Therapeutics CAPR Stock Holding History

HighTower Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-35,200	Closed	-$142K	–	3855
2025 Q2	$142K	Sell	35,200 -6,400	-15%	-$67.6K	﹤0.01%	3396
2025 Q1	$111K	Buy	41,600 +10,000	+32%	+$139K	﹤0.01%	3340
2024 Q4	$130K	Buy	31,600 +11,600	+58%	+$203K	﹤0.01%	3316
2024 Q3	$96K	Buy	20,000 +11,000	+122%	+$54.4K	﹤0.01%	3322
2024 Q2	$2.7K	Sell	9,000 -15,000	-63%	-$83.6K	﹤0.01%	3514
2024 Q1	$7.2K	Buy	+24,000	New	+$116K	﹤0.01%	3420
2022 Q3	–	Sell	-7,000	Closed	-$11K	–	3181
2022 Q2	$11K	Buy	7,000 +6,890	+6,264%	+$24.4K	﹤0.01%	3055
2022 Q1	$5K	Buy	+110	New	+$434	﹤0.01%	3267
2021 Q3	–	Sell	-11,300	Closed	-$16K	–	3212
2021 Q2	$16K	Buy	+11,300	New	+$47.9K	﹤0.01%	2966
2021 Q1	–	Sell	-310	Closed	-$49K	–	3071
2020 Q4	$49K	Sell	310 -9,690	-97%	-$42K	﹤0.01%	2413
2020 Q3	$14K	Buy	+10,000	New	+$58.3K	﹤0.01%	2391

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HighTower Advisors's CAPR Position: Q4 2025 in Review

HighTower Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2025, closing a stake of 1,200 shares — an estimated $8.65K sold.

HighTower Advisors first reported a position in CAPR in Q2 2020 and held it in 17 quarters. The position peaked at $215K in Q3 2021. 132 funds tracked by Wall St. Rank hold CAPR as of Q4 2025.

HighTower Advisors reported no remaining Capricor Therapeutics position as of Q4 2025 after selling out during the quarter.
HighTower Advisors sold 1,200 Capricor Therapeutics shares in Q4 2025, an estimated $8.65K.
HighTower Advisors first reported a position in Capricor Therapeutics in Q2 2020 and held it in 17 quarters.
HighTower Advisors's Capricor Therapeutics position peaked at $215K in Q3 2021.
132 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2025.

Based on HighTower Advisors's 13F filing for Q4 2025, filed 6 Feb 2026.